BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
435
Employees435
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
435
Employees435

BCRX Key Statistics

Market cap
2.48B
Market cap2.48B
Price-Earnings ratio
8.19
Price-Earnings ratio8.19
Dividend yield
Dividend yield
Average volume
5.20M
Average volume5.20M
High today
$9.94
High today$9.94
Low today
$9.80
Low today$9.80
Open price
$9.71
Open price$9.71
Volume
965.00
Volume965.00
52 Week high
$11.31
52 Week high$11.31
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

The current BioCryst(BCRX) stock price is $9.80, with a market capitalization of 2.48B. The stock trades at a price-to-earnings (P/E) ratio of 8.19.

As of 2026-04-10, BioCryst(BCRX) stock has fluctuated between $9.80 and $9.94. The current price stands at $9.80, placing the stock 0.0% above today's low and -1.4% off the high.

The BioCryst(BCRX)'s current trading volume is 965, compared to an average daily volume of 5.2M.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.31 at its peak.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.31 at its peak.

BCRX News

Simply Wall St 2d
A Look At BioCryst Pharmaceuticals Valuation After New R&D Leadership Appointment

BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties...

A Look At BioCryst Pharmaceuticals Valuation After New R&D Leadership Appointment
TipRanks 3d
BioCryst price target raised to $14 from $13 at RBC Capital

RBC Capital raised the firm’s price target on BioCryst (BCRX) to $14 from $13 and keeps an Outperform rating on the shares as part of the firm’s broader researc...

Simply Wall St 3d
R&D Leadership Shake-Up at BioCryst Could Be A Game Changer For Its Pipeline Strategy

BioCryst Pharmaceuticals recently appointed Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer, bringing experience from senior R&D leadership...

R&D Leadership Shake-Up at BioCryst Could Be A Game Changer For Its Pipeline Strategy

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

More BCRX News

TipRanks 4d
BioCryst appoints Sandeep Menon as chief research and development officer

BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served...

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.